Nektar Therapeutics (NKTR) Stock Price, Quote & News

Company Profile

Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally. It develops rezpegaldesleukin, which is in Phase 2b to treat underlying immune system imbalance in people with autoimmune disorders and inflammatory diseases; NKTR-0165 to treat ulcerative colitis, vitiligo, and multiple sclerosis; NKTR-0166 to treat autoimmune disease; NKTR-422 to treat fibrotic diseases; and NKTR-255 to treat...

Industry: Biotechnology

Sector: Healthcare

Phone: 415 482 5300

Fax: 415 339 5300

Website: www.nektar.com

Address:

455 Mission Bay Boulevard South, San Francisco, United States

re1ter May. 14 at 11:40 PM

$NKTR All these complaints about dilution....33.9 million shares outstanding is historically very low. They project $800 million in cash and equivalents at year end which would be 30% of today's market cap. The hissy fit the market is having currently will end and the strong position of this company will again be the focus. I remain bullish.

1 · Reply

buyandsold May. 14 at 6:23 PM

$NKTR I knew there was a reason I should have taken that advice to scale into a big position.

2 · Reply

calbucs May. 14 at 6:07 PM

$NKTR 3 major banks funded them at $92 , surely they are not just gonna bent over and just take it . Maybe it is that easy . From $109 to this , Short funds are recouping their losses . Aholes !

0 · Reply

ShortNKTR May. 14 at 5:05 PM

$NKTR Stay away from this. The CEO killed it. You do not dilute just because you can. He continues to destroy shareholder value by being clueless.

0 · Reply

BK217 May. 14 at 3:38 PM

$NKTR does anyone here actually enjoy bottoming

3 · Reply

Quantumup May. 14 at 3:17 PM

Jefferies⬆️ $APGE's PT to $120 and⬆️Zumi's risk-adj MonoTx rev to $2.5B, reiterated at Buy, and said: APGE's Ph2 APEX Part B 16wk AD data is exp Q2. LLY SNY - REGN KYMR $NKTR $CRVS Here's what else Jefferies had to say in its note to investors: https://x.com/Quantumup1/status/2054943651688493232?s=20

0 · Reply

calbucs May. 14 at 1:35 PM

$NKTR Is today the day we finally get a positive day , it’s been 2 weeks of nothing but down ! That’s enough .

2 · Reply

BK217 May. 13 at 9:02 PM

$NKTR this catalyst desert is drier than my stepmoms box

1 · Reply

calbucs May. 13 at 8:02 PM

$NKTR Shorts on the Hunt , scaring people off . Straight down since 2nd offering ! They should have waited on that BS , shorts are piling on the company with over 1bill in cash now ? Dumb ! Add at these levels , has to level off here . Cant see this below $70 . We shall see though

0 · Reply

buyandsold May. 13 at 7:27 PM

$NKTR Straight up trash action since the $92 offering. I'd be pissed if I'd been invited to a special club to participate in that. Actually I'm pissed that I bought around that price without the invitation.

0 · Reply

Nektar price target lowered to $80 from $95 at Wedbush

2026-05-08T11:17:20.000Z - 6 days ago

Nektar price target raised to $192 from $105 at Piper Sandler

May 7, 2026, 5:00 PM EDT - 7 days ago

Nektar Therapeutics Earnings Call Transcript: Q1 2026

2026-05-07T20:52:57.000Z - 7 days ago

Nektar reports Q1 adjusted EPS ($1.82), consensus ($1.48)

May 7, 2026, 4:15 PM EDT - 7 days ago

Nektar Therapeutics Reports First Quarter 2026 Financial Results

May 1, 2026, 4:39 PM EDT - 13 days ago

Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Apr 28, 2026, 6:00 PM EDT - 16 days ago

Nektar to Announce Financial Results for the First Quarter on Thursday, May 7, 2026, After Close of U.S.-Based Financial Markets

Apr 23, 2026, 4:15 PM EDT - 21 days ago

Nektar Therapeutics Announces Closing of $373.8 Million Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares

Apr 21, 2026, 9:30 PM EDT - 23 days ago

Nektar Therapeutics Announces Pricing of Upsized $325 Million Public Offering

2026-04-21T15:55:35.000Z - 23 days ago

Nektar price target raised to $95 from $70 at Wedbush

2026-04-21T10:56:02.000Z - 23 days ago

Nektar price target raised to $151 from $123 at Citi

2026-04-20T20:06:22.000Z - 24 days ago

Nektar announces $250M common stock offering

Apr 20, 2026, 4:01 PM EDT - 24 days ago

Nektar Therapeutics Announces Proposed Public Offering

2026-04-20T16:07:46.000Z - 24 days ago

Nektar rises 28.2%

Apr 20, 2026, 11:43 AM EDT - 24 days ago

This Biotech Stock Soars on Hair Loss Trial Results. It's Not a Cure for Baldness.

2026-04-20T15:12:00.000Z - 24 days ago

Nektar rises 19.4%

2026-04-20T15:02:50.000Z - 24 days ago

Nektar price target raised to $185 from $165 at H.C. Wainwright

Apr 20, 2026, 8:00 AM EDT - 24 days ago

Nektar Therapeutics Transcript: Study update

2026-04-20T11:49:42.000Z - 24 days ago

Nektar reports new results from Phase 2b REZOLVE-AA study

Apr 20, 2026, 7:30 AM EDT - 24 days ago

52-Week Topline Results from 16-Week Blinded Treatment Extension of REZOLVE-AA Demonstrate Deepening of Responses in Severe-to-Very-Severe Alopecia Areata with Rezpegaldesleukin

Apr 19, 2026, 12:00 PM EDT - 25 days ago

Nektar to Hold Conference Call to Discuss 52-Week Topline Results from the 16-Week Extension Treatment Period for its REZOLVE-AA Phase 2b Study of Rezpegaldesleukin in Alopecia Areata on April 20, 2026

Apr 9, 2026, 8:23 AM EDT - 5 weeks ago

NEKTAR THERAPEUTICS (NKTR) DEADLINE ALERT Bernstein Liebhard LLP Reminds Nektar Therapeutics Investors of Upcoming Deadline

2026-04-07T14:25:39.000Z - 5 weeks ago

Citi opens ‘upside 30-day catalyst watch’ on Nektar into data

Mar 31, 2026, 2:50 PM EDT - 6 weeks ago

NKTR Stockholders Have Rights – If You Lost Money Investing in Nektar Therapeutics Contact Robbins LLP for Information About Recovering Your Losses

2026-03-29T15:40:07.000Z - 6 weeks ago

Nektar announces data from Phase 2b Rezolve-AD, Rezolve-AA studies

Mar 28, 2026, 12:36 PM EDT - 6 weeks ago

Data from Phase 2b REZOLVE-AD and REZOLVE-AA Studies of Rezpegaldesleukin Presented at 2026 American Academy of Dermatology Annual Meeting

2026-03-24T11:15:28.000Z - 7 weeks ago

Nektar initiated with a Neutral at Wedbush

Mar 20, 2026, 10:00 AM EDT - 7 weeks ago

Data from Phase 2b Studies for Rezpegaldesleukin Accepted for Two Oral Presentations at the 2026 American Academy of Dermatology Annual Meeting

2026-03-17T09:45:28.000Z - 2 months ago

Nektar initiated with a Buy at TD Cowen

2026-03-16T10:42:20.000Z - 2 months ago

Nektar price target raised to $123 from $102 at Citi

Mar 12, 2026, 5:00 PM EDT - 2 months ago

Nektar Therapeutics Earnings Call Transcript: Q4 2025

Mar 12, 2026, 4:15 PM EDT - 2 months ago

Nektar Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results

Mar 10, 2026, 5:58 PM EDT - 2 months ago

NEKTAR THERAPEUTICS (NKTR) INVESTOR ALERT Investors With Large Losses in Nektar Therapeutics Should Contact Bernstein Liebhard LLP To Discuss Their Rights

Mar 9, 2026, 7:10 AM EDT - 2 months ago

Grabar Law Office Investigates Claims on Behalf of Long-Term Shareholders of Nektar Therapeutics, (NKTR)

Mar 4, 2026, 9:10 AM EST - 2 months ago

Nektar Therapeutics Transcript: TD Cowen 46th Annual Health Care Conference

Feb 26, 2026, 6:00 PM EST - 2 months ago

Nektar to Announce Financial Results for the Fourth Quarter and Year-Ended 2025 on Thursday, March 12, 2026, After Close of U.S.-Based Financial Markets

Feb 24, 2026, 6:00 PM EST - 2 months ago

Nektar Therapeutics to Participate in Two Investor Conferences in March

Feb 17, 2026, 7:00 AM EST - 3 months ago

Nektar Therapeutics Announces Research Collaboration with UCSF and Dr. Stephen Hauser for NKTR-0165, a Tumor Necrosis Factor Receptor 2 (TNFR2) Antibody, in Multiple Sclerosis

Feb 13, 2026, 4:15 PM EST - 3 months ago

Nektar Therapeutics Announces Closing of $460 Million Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares

Feb 13, 2026, 9:30 AM EST - 3 months ago

Can NKTR Stock Sustain Its 1,000% Rally?

Feb 11, 2026, 10:23 PM EST - 3 months ago

Nektar Therapeutics Announces Pricing of Upsized $400 Million Public Offering

Feb 10, 2026, 8:00 AM EST - 3 months ago

Nektar Therapeutics Transcript: Study result

Feb 10, 2026, 7:00 AM EST - 3 months ago

New REZOLVE-AD Maintenance Data in Atopic Dermatitis Demonstrate Rezpegaldesleukin Resulted in Durable and New Responses Across Key Disease Measurements with Both Monthly and Quarterly Dosing

Feb 9, 2026, 4:15 PM EST - 3 months ago

Nektar to Hold Conference Call to Discuss Topline Results from the 36-Week Maintenance Period for its REZOLVE-AD Phase 2b Study of Rezpegaldesleukin in Atopic Dermatitis on February 10, 2026

Jan 15, 2026, 6:58 PM EST - 4 months ago

Nektar.io Introduces DIRT: Materials Management for the Construction Industry

Dec 16, 2025, 8:00 AM EST - 5 months ago

Nektar Therapeutics Transcript: Study Result

Dec 15, 2025, 6:00 PM EST - 5 months ago

Nektar to Hold Conference Call to Discuss Topline Results from the 36-Week Induction Treatment Period for its REZOLVE-AA Phase 2b Study of Rezpegaldesleukin in Alopecia Areata on December 16, 2025

Nov 20, 2025, 6:00 AM EST - 6 months ago

Nektar Therapeutics Transcript: Jefferies London Healthcare Conference 2025

Nov 8, 2025, 5:45 PM EST - 6 months ago

New Data from REZOLVE-AD Study of Rezpegaldesleukin Presented in Late-Breaking Oral Abstract Presentation at ACAAI 2025 Annual Scientific Meeting

Nov 6, 2025, 5:00 PM EST - 6 months ago

Nektar Therapeutics Earnings Call Transcript: Q3 2025

Nov 6, 2025, 4:15 PM EST - 6 months ago

Nektar Therapeutics Reports Third Quarter 2025 Financial Results

Oct 30, 2025, 6:00 PM EDT - 7 months ago

Nektar Therapeutics to Participate in the Jefferies Global Healthcare Conference in London

Oct 28, 2025, 6:00 PM EDT - 7 months ago

Nektar to Announce Financial Results for the Third Quarter on Thursday, November 6, 2025, After Close of U.S.-Based Financial Markets

Oct 28, 2025, 12:36 PM EDT - 7 months ago

San Francisco is making a comeback. So are these stocks from the City by the Bay

MAZE REAL

Oct 22, 2025, 8:00 AM EDT - 7 months ago

Data from REZOLVE-AD Phase 2b Study for Rezpegaldesleukin Accepted for Late-Breaking Oral Abstract Presentation at ACAAI 2025 Annual Scientific Meeting

Sep 18, 2025, 8:45 AM EDT - 8 months ago

Nektar Presents New Data from REZOLVE-AD Phase 2b Study for Rezpegaldesleukin in Late-Breaker Oral Presentation at EADV 2025

Sep 15, 2025, 2:30 PM EDT - 8 months ago

Nektar Therapeutics Transcript: Stifel Virtual Immunology and Inflammation Forum

Sep 10, 2025, 10:30 AM EDT - 8 months ago

Nektar Therapeutics Transcript: H.C. Wainwright 27th Annual Global Investment Conference

Sep 9, 2025, 7:00 AM EDT - 8 months ago

Nektar Announces REZOLVE-AD Phase 2b Results for Rezpegaldesleukin Selected for Late-Breaker Oral Presentation at EADV 2025

Sep 3, 2025, 7:00 PM EDT - 9 months ago

Nektar Therapeutics to Participate in Two Investor Conferences in September

Aug 7, 2025, 5:00 PM EDT - 10 months ago

Nektar Therapeutics Earnings Call Transcript: Q2 2025

Aug 7, 2025, 4:15 PM EDT - 10 months ago

Nektar Therapeutics Reports Second Quarter 2025 Financial Results

Jul 31, 2025, 6:00 PM EDT - 10 months ago

Nektar to Announce Financial Results for the Second Quarter on Thursday, August 7, 2025, After Close of U.S.-Based Financial Markets

Jul 29, 2025, 9:00 AM EDT - 10 months ago

Nektar Therapeutics Receives Fast Track Designation for Rezpegaldesleukin for the Treatment of Severe-to-Very Severe Alopecia Areata

Jul 2, 2025, 4:15 PM EDT - 11 months ago

Nektar Therapeutics Announces Closing of $115 Million Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares

Jul 1, 2025, 7:17 AM EDT - 11 months ago

Nektar Therapeutics Announces Pricing of $100 Million Public Offering

Jun 24, 2025, 1:20 PM EDT - 11 months ago

Nektar Therapeutics Is Up 150%: What's Happening With NKTR Stock?

Jun 24, 2025, 8:15 AM EDT - 11 months ago

Nektar Therapeutics Transcript: Study Update

Jun 24, 2025, 7:35 AM EDT - 11 months ago

Nektar Therapeutics' experimental eczema drug meets main goals of mid-stage trial

Jun 24, 2025, 7:30 AM EDT - 11 months ago

REZOLVE-AD Phase 2b Study of Rezpegaldesleukin Meets Primary and Key Secondary Endpoints in Patients with Moderate-to-Severe Atopic Dermatitis

re1ter May. 14 at 11:40 PM

1 · Reply

buyandsold May. 14 at 6:23 PM

$NKTR I knew there was a reason I should have taken that advice to scale into a big position.

2 · Reply

calbucs May. 14 at 6:07 PM

$NKTR 3 major banks funded them at $92 , surely they are not just gonna bent over and just take it . Maybe it is that easy . From $109 to this , Short funds are recouping their losses . Aholes !

0 · Reply

ShortNKTR May. 14 at 5:05 PM

$NKTR Stay away from this. The CEO killed it. You do not dilute just because you can. He continues to destroy shareholder value by being clueless.

0 · Reply

BK217 May. 14 at 3:38 PM

$NKTR does anyone here actually enjoy bottoming

3 · Reply

Quantumup May. 14 at 3:17 PM

0 · Reply

calbucs May. 14 at 1:35 PM

$NKTR Is today the day we finally get a positive day , it’s been 2 weeks of nothing but down ! That’s enough .

2 · Reply

BK217 May. 13 at 9:02 PM

$NKTR this catalyst desert is drier than my stepmoms box

1 · Reply

calbucs May. 13 at 8:02 PM

0 · Reply

buyandsold May. 13 at 7:27 PM

0 · Reply

ShortNKTR May. 13 at 4:27 PM

$NKTR From 110 to 75. This is not close to stoppping. They really want it low 60s. How many bought above 92? sad news. Its not going back anytime soon. It will bottom low 60s and consolidate there for months.

0 · Reply

sterling23 May. 13 at 3:59 PM

$NKTR got burned here before but looks like it's time

0 · Reply

BK217 May. 13 at 3:31 PM

$NKTR could see this get as low as $55 in the coming weeks

2 · Reply

PercyFinn May. 13 at 2:04 PM

$NKTR Here is what Wedbush"s consistent neutral rating (basically meaning: sell), which started 03/24/2026, who happily keeps on lowering a PT for NKTR regardless of tremendous Rezpeg's results means: 1. Being a D.ck House invalidating Rezpeg's chances for commercial success even without Black Box Warning 2. Being in cahoots with JAK Inhibitors or TCIs makers, who do have Black Box Warnings 3. Acting on behalf of possible suitor/buyer 4. Just being a Good Guy trying to find a reasonable entry point. Stick around, ignore Wedbush noise.

1 · Reply

Pihedgy May. 13 at 2:00 PM

$NKTR these shorts are fcking legends.

0 · Reply

Pihedgy May. 13 at 11:45 AM

$NKTR let’s get back above 80 today. I can’t take anymore red candles.

0 · Reply

calbucs May. 12 at 9:39 PM

$NKTR Strong recovery to end the day ! , let’s get back on track on our way to $100.

0 · Reply

ShortNKTR May. 12 at 2:02 PM

$NKTR from 109 to 77. something is wrong here

0 · Reply

BK217 May. 12 at 1:28 PM

$NKTR dem shorts are piling on

1 · Reply

PercyFinn May. 12 at 1:28 PM

$NKTR It feels like someone is paying Wedbush for inflicting a war crime on NKTR, doesn't it?

1 · Reply

Pihedgy May. 11 at 6:45 PM

$NKTR people mock Wedbush and rightly so but they’ve been the most right about the general SP direction over the past couple of months

1 · Reply

george4it May. 11 at 6:14 PM

$NKTR 300 more added at 77. Keep it coming please and thank you.

0 · Reply

Market Cap	2.57B
Revenue (ttm)	55.23M
Net Income (ttm)	-164.08M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-297.08%
Debt to Equity Ratio	0.00

Volume	788,500
Avg Vol	1,000,958
Day's Range	N/A - N/A
Shares Out	33.79M
Stochastic %K	8%
Beta	1.24
Analysts	Strong Sell
Price Target	$153.25